血栓六项的临床意义

2021-10-17 检验星空 检验星空

一文读懂!

血浆凝血酶-抗血酶复合物(TAT

凝血酶生成是静脉血栓形成的关键环节,作为凝血酶与抗凝血酶 Ⅲ 1:1结合形成的复合物,TAT可作为凝血酶生成的分子标志物,直接证实凝血系统的活化。血浆0.4-120ngmL:4.08ng/mL;凝血酶活化的指标,升高提示血液高凝状态,辅助诊断DIC,检测溶栓效果及血栓复发情况。

纤溶酶-α2纤溶酶抑制剂复合物(PIC

纤溶酶生成后迅速与a2纤溶酶抑制剂1:1结合形成纤溶酶-a2纤溶酶抑制剂复合物(PIC),直接反映纤溶酶的生成,可用于纤溶类疾病的辅助诊断及疗效观察。<0.85ug/mL,纤溶活化的指标,升高提示血栓形成,纤溶活化。辅助诊断DICpre-DC及其它血栓性疾病,监测溶栓效果。

血栓调节蛋白(TM

内皮细胞发生病变或受损时,常引起TM的表达、分泌异常、释放入血,从而引起TM含量变化,因此可作为内皮细胞损伤的标志物。3.82-13.35TU/mL;内皮损伤的指标,升高提示内皮系统受损、辅助诊断DC,动脉粥样硬化。

组织纤溶酶原激活物/纤溶酶原激活物抑制剂-1复合物(t-PAIC

t-PAIC水平与t-PA浓度及血管内皮损伤程度呈正相关,是评估两者的直接标志物。健康男性<17.13ng/mL;健康女性<10.52ng/mL。内皮损伤及纤溶活化的指标,升高可提内皮损伤及纤溶活化,辅助诊断静脉血栓、心肌梗塞,判断术后血管内皮系统修复程度,监测溶栓效果。

D-二聚体( D-Dimer

来源于纤溶酶溶解的交联纤维蛋白凝块,主要反映纤维蛋白溶解功能。0-0.5 ug/ml(FEU) ,纤溶产物,升高提示血栓形成,辅助诊断继发性纤溶相关疾病,鉴别原发性及继发性纤溶,监测溶栓效果及血栓复发情况。

纤维蛋白()降解产物(FDP

纤维蛋白(原)降解产物主要反映纤维蛋白溶解功能。<5.0ug/mL;纤溶产物,升高提示纤溶活化,辅助诊断原发性及继发性纤溶相关疾病,肿瘤、妊高症,肝脏疾病,监测血栓性疾病进程。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1184085, encodeId=e808118408502, content=明天再来继续学, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/fFgUJknhibCy1mxLxGwk0ndVfWXmBh8AOibSFDqsSgnoeicu2QjNDYn0g/0, createdBy=c24f1943525, createdName=覃医生, createdTime=Thu Jan 13 23:56:03 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061474, encodeId=27ca10614e437, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25ff5638018, createdName=ms4000000178769572, createdTime=Mon Oct 18 14:51:59 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061415, encodeId=ead61061415b7, content=好 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211018/cf8f772ab38148e8ac2cb234229f8f71/4fea1ac6fb8a4a6ca1be5e0817ee1b81.jpg, createdBy=65685639002, createdName=我不是针对谁, createdTime=Mon Oct 18 10:32:15 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061390, encodeId=95a5106139069, content=溶酶生成后迅速与a2纤溶酶抑制剂1:1结, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Oct 18 08:55:33 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061376, encodeId=c34410613e646, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Oct 18 07:08:49 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061367, encodeId=7544106136ea6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Oct 18 06:50:46 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061311, encodeId=2c701061311c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43ad5623541, createdName=ms2000000409663500, createdTime=Sun Oct 17 21:43:39 CST 2021, time=2021-10-17, status=1, ipAttribution=)]
    2022-01-13 覃医生

    明天再来继续学

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1184085, encodeId=e808118408502, content=明天再来继续学, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/fFgUJknhibCy1mxLxGwk0ndVfWXmBh8AOibSFDqsSgnoeicu2QjNDYn0g/0, createdBy=c24f1943525, createdName=覃医生, createdTime=Thu Jan 13 23:56:03 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061474, encodeId=27ca10614e437, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25ff5638018, createdName=ms4000000178769572, createdTime=Mon Oct 18 14:51:59 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061415, encodeId=ead61061415b7, content=好 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211018/cf8f772ab38148e8ac2cb234229f8f71/4fea1ac6fb8a4a6ca1be5e0817ee1b81.jpg, createdBy=65685639002, createdName=我不是针对谁, createdTime=Mon Oct 18 10:32:15 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061390, encodeId=95a5106139069, content=溶酶生成后迅速与a2纤溶酶抑制剂1:1结, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Oct 18 08:55:33 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061376, encodeId=c34410613e646, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Oct 18 07:08:49 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061367, encodeId=7544106136ea6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Oct 18 06:50:46 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061311, encodeId=2c701061311c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43ad5623541, createdName=ms2000000409663500, createdTime=Sun Oct 17 21:43:39 CST 2021, time=2021-10-17, status=1, ipAttribution=)]
    2021-10-18 ms4000000178769572

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1184085, encodeId=e808118408502, content=明天再来继续学, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/fFgUJknhibCy1mxLxGwk0ndVfWXmBh8AOibSFDqsSgnoeicu2QjNDYn0g/0, createdBy=c24f1943525, createdName=覃医生, createdTime=Thu Jan 13 23:56:03 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061474, encodeId=27ca10614e437, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25ff5638018, createdName=ms4000000178769572, createdTime=Mon Oct 18 14:51:59 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061415, encodeId=ead61061415b7, content=好 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211018/cf8f772ab38148e8ac2cb234229f8f71/4fea1ac6fb8a4a6ca1be5e0817ee1b81.jpg, createdBy=65685639002, createdName=我不是针对谁, createdTime=Mon Oct 18 10:32:15 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061390, encodeId=95a5106139069, content=溶酶生成后迅速与a2纤溶酶抑制剂1:1结, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Oct 18 08:55:33 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061376, encodeId=c34410613e646, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Oct 18 07:08:49 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061367, encodeId=7544106136ea6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Oct 18 06:50:46 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061311, encodeId=2c701061311c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43ad5623541, createdName=ms2000000409663500, createdTime=Sun Oct 17 21:43:39 CST 2021, time=2021-10-17, status=1, ipAttribution=)]
    2021-10-18 我不是针对谁

    好 学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1184085, encodeId=e808118408502, content=明天再来继续学, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/fFgUJknhibCy1mxLxGwk0ndVfWXmBh8AOibSFDqsSgnoeicu2QjNDYn0g/0, createdBy=c24f1943525, createdName=覃医生, createdTime=Thu Jan 13 23:56:03 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061474, encodeId=27ca10614e437, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25ff5638018, createdName=ms4000000178769572, createdTime=Mon Oct 18 14:51:59 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061415, encodeId=ead61061415b7, content=好 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211018/cf8f772ab38148e8ac2cb234229f8f71/4fea1ac6fb8a4a6ca1be5e0817ee1b81.jpg, createdBy=65685639002, createdName=我不是针对谁, createdTime=Mon Oct 18 10:32:15 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061390, encodeId=95a5106139069, content=溶酶生成后迅速与a2纤溶酶抑制剂1:1结, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Oct 18 08:55:33 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061376, encodeId=c34410613e646, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Oct 18 07:08:49 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061367, encodeId=7544106136ea6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Oct 18 06:50:46 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061311, encodeId=2c701061311c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43ad5623541, createdName=ms2000000409663500, createdTime=Sun Oct 17 21:43:39 CST 2021, time=2021-10-17, status=1, ipAttribution=)]
    2021-10-18 查查佳佳

    溶酶生成后迅速与a2纤溶酶抑制剂1:1结

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1184085, encodeId=e808118408502, content=明天再来继续学, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/fFgUJknhibCy1mxLxGwk0ndVfWXmBh8AOibSFDqsSgnoeicu2QjNDYn0g/0, createdBy=c24f1943525, createdName=覃医生, createdTime=Thu Jan 13 23:56:03 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061474, encodeId=27ca10614e437, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25ff5638018, createdName=ms4000000178769572, createdTime=Mon Oct 18 14:51:59 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061415, encodeId=ead61061415b7, content=好 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211018/cf8f772ab38148e8ac2cb234229f8f71/4fea1ac6fb8a4a6ca1be5e0817ee1b81.jpg, createdBy=65685639002, createdName=我不是针对谁, createdTime=Mon Oct 18 10:32:15 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061390, encodeId=95a5106139069, content=溶酶生成后迅速与a2纤溶酶抑制剂1:1结, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Oct 18 08:55:33 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061376, encodeId=c34410613e646, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Oct 18 07:08:49 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061367, encodeId=7544106136ea6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Oct 18 06:50:46 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061311, encodeId=2c701061311c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43ad5623541, createdName=ms2000000409663500, createdTime=Sun Oct 17 21:43:39 CST 2021, time=2021-10-17, status=1, ipAttribution=)]
    2021-10-18 学医无涯

    学习一下

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1184085, encodeId=e808118408502, content=明天再来继续学, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/fFgUJknhibCy1mxLxGwk0ndVfWXmBh8AOibSFDqsSgnoeicu2QjNDYn0g/0, createdBy=c24f1943525, createdName=覃医生, createdTime=Thu Jan 13 23:56:03 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061474, encodeId=27ca10614e437, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25ff5638018, createdName=ms4000000178769572, createdTime=Mon Oct 18 14:51:59 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061415, encodeId=ead61061415b7, content=好 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211018/cf8f772ab38148e8ac2cb234229f8f71/4fea1ac6fb8a4a6ca1be5e0817ee1b81.jpg, createdBy=65685639002, createdName=我不是针对谁, createdTime=Mon Oct 18 10:32:15 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061390, encodeId=95a5106139069, content=溶酶生成后迅速与a2纤溶酶抑制剂1:1结, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Oct 18 08:55:33 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061376, encodeId=c34410613e646, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Oct 18 07:08:49 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061367, encodeId=7544106136ea6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Oct 18 06:50:46 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061311, encodeId=2c701061311c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43ad5623541, createdName=ms2000000409663500, createdTime=Sun Oct 17 21:43:39 CST 2021, time=2021-10-17, status=1, ipAttribution=)]
    2021-10-18 仁术2021

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1184085, encodeId=e808118408502, content=明天再来继续学, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/fFgUJknhibCy1mxLxGwk0ndVfWXmBh8AOibSFDqsSgnoeicu2QjNDYn0g/0, createdBy=c24f1943525, createdName=覃医生, createdTime=Thu Jan 13 23:56:03 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061474, encodeId=27ca10614e437, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25ff5638018, createdName=ms4000000178769572, createdTime=Mon Oct 18 14:51:59 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061415, encodeId=ead61061415b7, content=好 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211018/cf8f772ab38148e8ac2cb234229f8f71/4fea1ac6fb8a4a6ca1be5e0817ee1b81.jpg, createdBy=65685639002, createdName=我不是针对谁, createdTime=Mon Oct 18 10:32:15 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061390, encodeId=95a5106139069, content=溶酶生成后迅速与a2纤溶酶抑制剂1:1结, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Mon Oct 18 08:55:33 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061376, encodeId=c34410613e646, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Oct 18 07:08:49 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061367, encodeId=7544106136ea6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Oct 18 06:50:46 CST 2021, time=2021-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061311, encodeId=2c701061311c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43ad5623541, createdName=ms2000000409663500, createdTime=Sun Oct 17 21:43:39 CST 2021, time=2021-10-17, status=1, ipAttribution=)]
    2021-10-17 ms2000000409663500

    学习了

    0

相关资讯

细菌感染时,白细胞和C反应蛋白升高一致吗?

白细胞(white blood cell,WBC)和快速C反应蛋白(C-reactive protein ,CRP)都是细菌感染项指标,在发生细菌感染时,WBC和CRP是否会同步升高呢?

战疫下半场,检验医生必须知道的那些事!

2020年,随着我国疫情爆发,五万医护人员奔赴湖北前线,无数工作人员坚守在全国各地,共同谱写了人类历史上最悲壮也最成功的战疫之歌。

ICU“风暴”来袭,这类检验为何如此关键?

新冠肺炎疫情的爆发让“细胞因子风暴”进入大众视野。

离谱的“危急值”,猜的对开头**想不到结尾

医院的工作性质决定,每个人都是一个重要环节,在哪个环节上出现纰漏,都会给医院和病人造成或大或小的人身和经济损失,抑或是酿成医疗事故,造成不可挽回的局面。

如何防范二次爆发?专家:出武汉尽快推广应检尽检

武汉解封后,我们应该重点关注无症状感染者的问题,如果无症状感染者控制不到位的话,疫情仍有二次爆发风险。”中国人民大学经济研究所所长、健康经济学专家毛振华告诉人民日报健康客户端记者,为应对这

究竟如何,才能让临床相信检验科的结果?

实验室检查在感染性疾病的诊断和治疗过程中发挥着重要作用,其中降钙素原(procalcitonin,PCT)就是一种公认可用于诊断和监测细菌性感染的重要实验室检查项目。